Unilever is not giving up on GSK’s consumer business

on Jan 17, 2022
  • Unilever is still interested in buying GSK's consumer business after its $68.25 billion bid was rejected.
  • GSK will likely open negotiations with Unilever if it bumps up its proposal to more than $82 billion.
  • Unilever shareholders aren't sure if the company should spend so much on the acquisition.

Follow Invezz on Telegram, Twitter, and Google News for instant updates >

Shares of Unilever plc (LON: ULVR) slid 4.0% on Monday after the British multinational said it was still interested in buying GlaxoSmithKline plc’s (LON: GSK) consumer business.

GSK continues to reject Unilever’s proposals

Copy link to section

So far, GSK has rejected three of Unilever’s proposals, including the most recent one that was valued at $68.25 billion. While shareholders aren’t sure if Unilever should spend so much on the acquisition, the London-based company is convinced GSK’s consumer segment is a “strong strategic fit”.

The acquisition would create scale and a growth platform for the combined portfolio in the U.S., China and India, with further opportunities in other emerging markets.

If Unilever fails to strike a deal, GlaxoSmithKline will list its consumer business on the stock exchange as it had originally planned.

As a separate, publicly-traded company, this unit could be valued at roughly $100 billion, which is why Bluebell Capital Partners’ Marco Taricco also sees Unilever’s bid as “underwhelming”.  

Featured Broker

Looking to invest?

Invest globally in stocks, options, futures, currencies, bonds and funds from a single unified platform, with our highest-rated broker.


Will Unilever bump up its bid?

Copy link to section

The U.S. pharmaceutical giant, Pfizer Inc, has a 32% ownership stake in GSK’s consumer unit. The two companies are likely to open negotiations with Unilever if it bumps up its bid. A source familiar with the matter said:

Are you looking for fast-news, hot-tips and market analysis? Sign-up for the Invezz newsletter, today.

Right now, there is more value in a spin-off. But if Unilever is ready to go north of $82 billion, then a dialogue could start.

If Unilever indeed makes such an offer, it will be one of the largest deals on a global scale since the advent of the Coronavirus pandemic. But Quilter Cheviot’s Chris Beckett thinks it’s unlikely to happen.

Given vocal investor concern of late and Unilever’s share price reaction this morning, this could prevent a higher offer from materializing.


Copy expert traders easily with eToro. Invest in stocks like Tesla & Apple. Instantly trade ETFs like FTSE 100 & S&P 500. Sign-up in minutes.


eToro offers real assets only, no CFD products. eToro USA LLC and eToro USA Securities Inc.; Investing involves risk, including loss of principal; Not a recommendation.

Get demo account
GSK Pfizer UK Unilever Europe Manufacturing Stock Market World